Published in Infect Immun on March 22, 2010
Bacteriophage adhering to mucus provide a non-host-derived immunity. Proc Natl Acad Sci U S A (2013) 3.86
Phenotypic and genotypic evidence for L-fucose utilization by Campylobacter jejuni. J Bacteriol (2010) 1.31
Transmigration route of Campylobacter jejuni across polarized intestinal epithelial cells: paracellular, transcellular or both? Cell Commun Signal (2013) 1.01
Protective effect of probiotics on Salmonella infectivity assessed with combined in vitro gut fermentation-cellular models. BMC Microbiol (2011) 0.98
Intestinal microbiome of poultry and its interaction with host and diet. Gut Microbes (2013) 0.98
The renaissance of bacillosamine and its derivatives: pathway characterization and implications in pathogenicity. Biochemistry (2014) 0.97
Recombinant probiotic expressing Listeria adhesion protein attenuates Listeria monocytogenes virulence in vitro. PLoS One (2012) 0.92
Divergent mechanisms of interaction of Helicobacter pylori and Campylobacter jejuni with mucus and mucins. Infect Immun (2013) 0.86
Defense and adaptation: the complex inter-relationship between Campylobacter jejuni and mucus. Front Cell Infect Microbiol (2012) 0.85
Mechanisms and therapeutic effectiveness of lactobacilli. J Clin Pathol (2015) 0.85
The interaction of Helicobacter pylori with the adherent mucus gel layer secreted by polarized HT29-MTX-E12 cells. PLoS One (2012) 0.85
Divergent roles of Salmonella pathogenicity island 2 and metabolic traits during interaction of S. enterica serovar typhimurium with host cells. PLoS One (2012) 0.85
N-glycosylation of Campylobacter jejuni surface proteins promotes bacterial fitness. Infect Immun (2013) 0.85
Detection of galectin-3 interaction with commensal bacteria. Appl Environ Microbiol (2013) 0.82
Interaction of microbes with mucus and mucins: recent developments. Gut Microbes (2013) 0.81
Recent Advances in Screening of Anti-Campylobacter Activity in Probiotics for Use in Poultry. Front Microbiol (2016) 0.81
Pathogenic E. coli exploits SslE mucinase activity to translocate through the mucosal barrier and get access to host cells. PLoS One (2015) 0.79
Involvement of the mannose receptor and p38 mitogen-activated protein kinase signaling pathway of the microdomain of the integral membrane protein after enteropathogenic Escherichia coli infection. Infect Immun (2012) 0.79
Insights into Campylobacter jejuni colonization of the mammalian intestinal tract using a novel mouse model of infection. Gut Microbes (2015) 0.79
Helicobacter suis affects the health and function of porcine gastric parietal cells. Vet Res (2016) 0.77
The role of probiotics in the inhibition of Campylobacter jejuni colonization and virulence attenuation. Eur J Clin Microbiol Infect Dis (2015) 0.76
Assessing Bacterial Interactions Using Carbohydrate-Based Microarrays. Microarrays (Basel) (2015) 0.75
Protective Effect of Carnobacterium spp. against Listeria monocytogenes during Host Cell Invasion Using In vitro HT29 Model. Front Cell Infect Microbiol (2016) 0.75
Microbes in gastrointestinal health and disease. Gastroenterology (2008) 4.65
A point-source outbreak of campylobacteriosis associated with consumption of raw milk. J Infect Dis (1985) 3.81
MUC1 cell surface mucin is a critical element of the mucosal barrier to infection. J Clin Invest (2007) 2.90
Tight junction proteins claudin-1 and occludin control hepatitis C virus entry and are downregulated during infection to prevent superinfection. J Virol (2008) 2.84
Bacterial secreted proteins are required for the internaliztion of Campylobacter jejuni into cultured mammalian cells. Mol Microbiol (1999) 2.60
Culture media for the isolation of campylobacters. Int J Food Microbiol (1995) 2.23
Extracellular MUC3 mucin secretion follows adherence of Lactobacillus strains to intestinal epithelial cells in vitro. Gut (2003) 2.00
Overview of gut flora and probiotics. Int J Food Microbiol (1998) 1.99
Campylobacter jejuni 81-176 associates with microtubules and dynein during invasion of human intestinal cells. Infect Immun (1999) 1.92
Growth adaptation to methotrexate of HT-29 human colon carcinoma cells is associated with their ability to differentiate into columnar absorptive and mucus-secreting cells. Cancer Res (1990) 1.85
Host-pathogen interactions in Campylobacter infections: the host perspective. Clin Microbiol Rev (2008) 1.76
Mechanisms of action of probiotics: recent advances. Inflamm Bowel Dis (2009) 1.75
Campylobacter jejuni survives within epithelial cells by avoiding delivery to lysosomes. PLoS Pathog (2008) 1.59
Disruption of tight junctions and induction of proinflammatory cytokine responses in colonic epithelial cells by Campylobacter jejuni. Infect Immun (2006) 1.54
Tight junctions as targets of infectious agents. Biochim Biophys Acta (2008) 1.47
Transepithelial migration of Toxoplasma gondii involves an interaction of intercellular adhesion molecule 1 (ICAM-1) with the parasite adhesin MIC2. Cell Microbiol (2005) 1.42
Molecular population genetic analysis of Campylobacter jejuni HS:19 associated with Guillain-Barré syndrome and gastroenteritis. J Infect Dis (2001) 1.40
Motility of Campylobacter jejuni in a viscous environment: comparison with conventional rod-shaped bacteria. J Gen Microbiol (1988) 1.38
Fibronectin-facilitated invasion of T84 eukaryotic cells by Campylobacter jejuni occurs preferentially at the basolateral cell surface. Infect Immun (2002) 1.36
Probiotics reduce enterohemorrhagic Escherichia coli O157:H7- and enteropathogenic E. coli O127:H6-induced changes in polarized T84 epithelial cell monolayers by reducing bacterial adhesion and cytoskeletal rearrangements. Infect Immun (2005) 1.33
Campylobacter jejuni motility and invasion of Caco-2 cells. Infect Immun (1995) 1.32
The probiotic Escherichia coli strain Nissle 1917 interferes with invasion of human intestinal epithelial cells by different enteroinvasive bacterial pathogens. FEMS Immunol Med Microbiol (2004) 1.31
Role of the small Rho GTPases Rac1 and Cdc42 in host cell invasion of Campylobacter jejuni. Cell Microbiol (2007) 1.24
Campylobacter jejuni response to human mucin MUC2: modulation of colonization and pathogenicity determinants. J Med Microbiol (2008) 1.19
Campylobacter jejuni adhere to and invade chicken intestinal epithelial cells in vitro. Microbiology (2007) 1.14
Campylobacter jejuni inhibits the absorptive transport functions of Caco-2 cells and disrupts cellular tight junctions. Microbiology (2005) 1.13
Campylobacter reactive arthritis: a systematic review. Semin Arthritis Rheum (2007) 1.13
Transcellular translocation of Campylobacter jejuni across human polarised epithelial monolayers. FEMS Microbiol Lett (1999) 1.08
Transport of lipophilic drug molecules in a new mucus-secreting cell culture model based on HT29-MTX cells. Pharm Res (2001) 1.07
Active migration into the subcellular space precedes Campylobacter jejuni invasion of epithelial cells. Cell Microbiol (2008) 1.06
Effect of mucin on Campylobacter jejuni association and invasion on HEp-2 cells. Microb Pathog (1988) 1.05
Investigating the effects of dietary probiotic feeding regimens on broiler chicken production and Campylobacter jejuni presence. Poult Sci (2008) 1.03
Strain-specific probiotic (Lactobacillus helveticus) inhibition of Campylobacter jejuni invasion of human intestinal epithelial cells. FEMS Microbiol Lett (2009) 0.97
Evaluation of an avian-specific probiotic to reduce the colonization and shedding of Campylobacter jejuni in broilers. Avian Dis (1998) 0.95
Mechanisms of action of probiotics in intestinal diseases. ScientificWorldJournal (2007) 0.95
Immune response to and histopathology of Campylobacter jejuni infection in ferrets (Mustela putorius furo). Comp Med (2009) 0.94
Enhanced microscopic definition of Campylobacter jejuni 81-176 adherence to, invasion of, translocation across, and exocytosis from polarized human intestinal Caco-2 cells. Infect Immun (2008) 0.93
Invasion of human epithelial cells by Campylobacter upsaliensis. Cell Microbiol (2003) 0.92
In vitro and ex vivo intestinal tissue models to measure mucoadhesion of poly (methacrylate) and N-trimethylated chitosan polymers. Pharm Res (2005) 0.91
Disruption of colonic barrier function and induction of mediator release by strains of Campylobacter jejuni that invade epithelial cells. World J Gastroenterol (2008) 0.86
Antagonistic activities of several bacteria on in vitro growth of 10 strains of Campylobacter jejuni/coli. Int J Food Microbiol (2004) 0.85
Probiotics prevent enterohaemorrhagic Escherichia coli O157:H7-mediated inhibition of interferon-gamma-induced tyrosine phosphorylation of STAT-1. Microbiology (2009) 0.84
Probiotic bacteria are antagonistic to Salmonella enterica and Campylobacter jejuni and influence host lymphocyte responses in human microbiota-associated immunodeficient and immunocompetent mice. Mol Nutr Food Res (2009) 0.84
Postinfectious irritable bowel syndrome: a long-term consequence of bacterial gastroenteritis. J Food Prot (2007) 0.82
The gut flora as a forgotten organ. EMBO Rep (2006) 7.42
Gut microbiota composition correlates with diet and health in the elderly. Nature (2012) 6.94
Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology (2005) 5.75
Composition, variability, and temporal stability of the intestinal microbiota of the elderly. Proc Natl Acad Sci U S A (2010) 5.02
Irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease: a real association or reflection of occult inflammation? Am J Gastroenterol (2010) 4.45
Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol (2006) 3.24
Culture-independent analyses of temporal variation of the dominant fecal microbiota and targeted bacterial subgroups in Crohn's disease. J Clin Microbiol (2006) 2.93
Multireplicon genome architecture of Lactobacillus salivarius. Proc Natl Acad Sci U S A (2006) 2.43
Exploring the diversity of the bifidobacterial population in the human intestinal tract. Appl Environ Microbiol (2009) 2.34
Hypothalamic-pituitary-gut axis dysregulation in irritable bowel syndrome: plasma cytokines as a potential biomarker? Gastroenterology (2006) 2.28
Divergent metabolic outcomes arising from targeted manipulation of the gut microbiota in diet-induced obesity. Gut (2012) 2.24
Functional genome analysis of Bifidobacterium breve UCC2003 reveals type IVb tight adherence (Tad) pili as an essential and conserved host-colonization factor. Proc Natl Acad Sci U S A (2011) 2.22
Commensal-induced regulatory T cells mediate protection against pathogen-stimulated NF-kappaB activation. PLoS Pathog (2008) 2.21
The role of substance P in inflammatory disease. J Cell Physiol (2004) 2.19
Effect of broad- and narrow-spectrum antimicrobials on Clostridium difficile and microbial diversity in a model of the distal colon. Proc Natl Acad Sci U S A (2010) 2.11
Bifidobacterial surface-exopolysaccharide facilitates commensal-host interaction through immune modulation and pathogen protection. Proc Natl Acad Sci U S A (2012) 2.09
Celiac disease and irritable bowel-type symptoms. Am J Gastroenterol (2002) 2.07
Differential expression of toll-like receptors in patients with irritable bowel syndrome. Am J Gastroenterol (2010) 2.02
Rapid and noninvasive metabonomic characterization of inflammatory bowel disease. J Proteome Res (2007) 1.99
Enterococcus faecalis metalloprotease compromises epithelial barrier and contributes to intestinal inflammation. Gastroenterology (2011) 1.96
Genetic modifiers of liver disease in cystic fibrosis. JAMA (2009) 1.88
Clinical presentation of and outcome for solitary rectal ulcer syndrome in children. J Pediatr Gastroenterol Nutr (2012) 1.84
Functional modulation of human intestinal epithelial cell responses by Bifidobacterium infantis and Lactobacillus salivarius. Immunology (2006) 1.73
The mycobacteria story in Crohn's disease. Am J Gastroenterol (2005) 1.71
Phylogenetic analysis of dysbiosis in ulcerative colitis during remission. Inflamm Bowel Dis (2013) 1.63
Differences in presentation and progression between severe FIC1 and BSEP deficiencies. J Hepatol (2010) 1.60
Bacteriophages φMR299-2 and φNH-4 can eliminate Pseudomonas aeruginosa in the murine lung and on cystic fibrosis lung airway cells. MBio (2012) 1.59
Human methanogen diversity and incidence in healthy and diseased colonic groups using mcrA gene analysis. BMC Microbiol (2008) 1.56
Cystic fibrosis-associated liver disease: a population-based study. J Pediatr (2004) 1.55
Disorders of a modern lifestyle: reconciling the epidemiology of inflammatory bowel diseases. Gut (2008) 1.54
Celiac disease and the transition from childhood to adulthood: a 28-year follow-up. Am J Gastroenterol (2004) 1.53
The gut microbiota and its relationship to diet and obesity: new insights. Gut Microbes (2012) 1.52
Radiologic imaging in cystic fibrosis: cumulative effective dose and changing trends over 2 decades. Chest (2011) 1.49
Radiation exposure from diagnostic imaging among patients with gastrointestinal disorders. Clin Gastroenterol Hepatol (2011) 1.48
Age-specific incidence of Helicobacter pylori. Gastroenterology (2006) 1.45
Microbiomic analysis of the bifidobacterial population in the human distal gut. ISME J (2009) 1.43
Culture-independent analysis of the gut microbiota in colorectal cancer and polyposis. Environ Microbiol (2008) 1.42
A prospective study of the oral manifestations of Crohn's disease. Clin Gastroenterol Hepatol (2005) 1.41
World Gastroenterology Organisation Global Guidelines: probiotics and prebiotics October 2011. J Clin Gastroenterol (2012) 1.39
A molecular analysis of fecal and mucosal bacterial communities in irritable bowel syndrome. Dig Dis Sci (2009) 1.39
Clostridium difficile carriage in elderly subjects and associated changes in the intestinal microbiota. J Clin Microbiol (2011) 1.34
Antimicrobial activity of lacticin 3,147 against clinical Clostridium difficile strains. J Med Microbiol (2007) 1.33
A randomized controlled study of mesalamine after acute diverticulitis: results of the DIVA trial. J Clin Gastroenterol (2013) 1.32
Categorization of the gut microbiota: enterotypes or gradients? Nat Rev Microbiol (2012) 1.31
Culture-independent analysis of desulfovibrios in the human distal colon of healthy, colorectal cancer and polypectomized individuals. FEMS Microbiol Ecol (2009) 1.31
Association of NOD2 with Crohn's disease in a homogenous Irish population. Eur J Hum Genet (2003) 1.30
Probiotic effects on inflammatory bowel disease. J Nutr (2007) 1.29
Mycobacterium avium subsp. Paratuberculosis (MAP) as a modifying factor in Crohn's disease. Inflamm Bowel Dis (2010) 1.27
Importance of parental conceptual model of illness in severe recurrent abdominal pain. Pediatrics (2003) 1.24
Bacterial DNA within granulomas of patients with Crohn's disease--detection by laser capture microdissection and PCR. Am J Gastroenterol (2004) 1.21
The vexed relationship between Clostridium difficile and inflammatory bowel disease: an assessment of carriage in an outpatient setting among patients in remission. Am J Gastroenterol (2009) 1.16
Enteric campylobacter: purging its secrets? Pediatr Res (2003) 1.16
Metabolic activity of the enteric microbiota influences the fatty acid composition of murine and porcine liver and adipose tissues. Am J Clin Nutr (2009) 1.15
Campylobacter jejuni adhere to and invade chicken intestinal epithelial cells in vitro. Microbiology (2007) 1.14
Molecular mechanisms of gastric epithelial cell adhesion and injection of CagA by Helicobacter pylori. Cell Commun Signal (2011) 1.13
Differential cytokine response from dendritic cells to commensal and pathogenic bacteria in different lymphoid compartments in humans. Am J Physiol Gastrointest Liver Physiol (2005) 1.12
Intestinal tuberculosis mimicking Crohn's disease: lessons relearned in a new era. Eur J Gastroenterol Hepatol (2007) 1.12
Mucosal cytokine imbalance in irritable bowel syndrome. Scand J Gastroenterol (2008) 1.11
Small intestinal bacterial overgrowth in nonalcoholic steatohepatitis: association with toll-like receptor 4 expression and plasma levels of interleukin 8. Dig Dis Sci (2010) 1.11
The normal intestinal microbiota. Curr Opin Infect Dis (2007) 1.11
Induction and activation of adaptive immune populations during acute and chronic phases of a murine model of experimental colitis. Dig Dis Sci (2010) 1.10
Enhanced cholinergic-mediated increase in the pro-inflammatory cytokine IL-6 in irritable bowel syndrome: role of muscarinic receptors. Am J Gastroenterol (2008) 1.10
Plasma cytokine profiles in females with irritable bowel syndrome and extra-intestinal co-morbidity. Am J Gastroenterol (2010) 1.10
Mucosal reactive oxygen species decrease virulence by disrupting Campylobacter jejuni phosphotyrosine signaling. Cell Host Microbe (2012) 1.08
Identification of a mutation in LARS as a novel cause of infantile hepatopathy. Mol Genet Metab (2012) 1.08
Loss of vagal anti-inflammatory effect: in vivo visualization and adoptive transfer. Am J Physiol Regul Integr Comp Physiol (2009) 1.07
Interaction of Cryptosporidium hominis and Cryptosporidium parvum with primary human and bovine intestinal cells. Infect Immun (2006) 1.06
Addressing the "Fas counterattack" controversy: blocking fas ligand expression suppresses tumor immune evasion of colon cancer in vivo. Cancer Res (2005) 1.06
Movers and shakers: influence of bacteriophages in shaping the mammalian gut microbiota. Gut Microbes (2012) 1.06
Pathogenesis of Helicobacter pylori infection. Helicobacter (2011) 1.05
Identification of TLR10 as a key mediator of the inflammatory response to Listeria monocytogenes in intestinal epithelial cells and macrophages. J Immunol (2013) 1.03
Targeting the microbiota to address diet-induced obesity: a time dependent challenge. PLoS One (2013) 1.01
Bifidobacterium infantis 35624 modulates host inflammatory processes beyond the gut. Gut Microbes (2013) 1.01
Protective effects of Lactobacillus rhamnosus [corrected] and Bifidobacterium infantis in murine models for colitis do not involve the vagus nerve. Am J Physiol Regul Integr Comp Physiol (2008) 1.00
Persistence of hepatitis C virus in a white population: associations with human leukocyte antigen class 1. Hum Immunol (2004) 0.99
Discussion on toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. Gastroenterology (2004) 0.98
Comparative chemical and biological characterization of the lipopolysaccharides of gastric and enterohepatic helicobacters. Helicobacter (2004) 0.98
The incidence of cyclic vomiting syndrome in children: population-based study. Am J Gastroenterol (2007) 0.97
Basic aspects and pharmacology of probiotics: an overview of pharmacokinetics, mechanisms of action and side-effects. Best Pract Res Clin Gastroenterol (2003) 0.96
Probiotics in perspective. Gastroenterology (2010) 0.96
The microbiota in inflammatory bowel disease. J Gastroenterol (2015) 0.95
Mechanisms of action of probiotics in intestinal diseases. ScientificWorldJournal (2007) 0.95
Looking in the mouth for Crohn's disease. Inflamm Bowel Dis (2010) 0.95
Fas ligand promotes tumor immune evasion of colon cancer in vivo. Cell Cycle (2006) 0.95
Contrasting effects of Bifidobacterium breve NCIMB 702258 and Bifidobacterium breve DPC 6330 on the composition of murine brain fatty acids and gut microbiota. Am J Clin Nutr (2012) 0.93
Role of radiologic imaging in irritable bowel syndrome: evidence-based review. Radiology (2011) 0.93
Helicobacter pylori lipopolysaccharide interacts with TFF1 in a pH-dependent manner. Gastroenterology (2008) 0.93
Gut microbiota: mining for therapeutic potential. Clin Gastroenterol Hepatol (2007) 0.93
Pellino3 ubiquitinates RIP2 and mediates Nod2-induced signaling and protective effects in colitis. Nat Immunol (2013) 0.92
Invasion of human epithelial cells by Campylobacter upsaliensis. Cell Microbiol (2003) 0.92
Differential regulation of Toll-like receptor signalling in spleen and Peyer's patch dendritic cells. Immunology (2010) 0.92
CD38 is associated with premenopausal and postmenopausal bone mineral density and postmenopausal bone loss. J Bone Miner Metab (2006) 0.92
Mechanism of protection of transepithelial barrier function by Lactobacillus salivarius: strain dependence and attenuation by bacteriocin production. Am J Physiol Gastrointest Liver Physiol (2012) 0.91
Fas ligand expressed in colon cancer is not associated with increased apoptosis of tumor cells in vivo. Int J Cancer (2003) 0.91
Host cell tropism underlies species restriction of human and bovine Cryptosporidium parvum genotypes. Infect Immun (2004) 0.91